Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)

NCT05063565 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT05063565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05063565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) With Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC)
Lead sponsor
Boston Scientific Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 3, 2023
Completion date
June 30, 2027
Enrollment
100 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma